95871 Mortality in Castration-Resistant Prostate Cancer Patients with Pre-existing Cardiovascular Comorbidities Receiving Oral Androgen Signaling Inhibitors

ABSTRACT IMPACT: Limited research has been conducted on the survival of men with castration-resistance prostate cancer (CRPC) with a pre-existing history of cardiovascular disease, receiving oral androgen signaling inhibitors. This study highlights all-cause and prostate cancer-specific mortality fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Asiri, Ibrahim M., Young, Henry N., Chen, Ronald C., Mandawat, Anant, Master, Viraj, Beach, Steven R.H., Cobran, Ewan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Translational Science, Policy, & Health Outcomes Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827985/
http://dx.doi.org/10.1017/cts.2021.719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827985/
http://dx.doi.org/10.1017/cts.2021.719

Ejemplares similares